News About: R&D
Samjin’s pyrimidinediones to enter Phase I clinical trials
Samjin Pharmaceutical, in collaboration with their drug development partner, the US based ImQuest Pharmaceutical Inc., have recently engaged in an effort to develop more active pyrimidinediones possessing this higher ...
Chunggei launches pioglitazone 15 mg
Chunggei Pharm has launched pioglitazone 15 mg in a bid to expand its presence in domestic type 2 diabetes market under joint marketing with Schnell Pharmaceuticals Inc.
Pioglitazone is used with a diet and exerci...
Novartis Korea holds launching symposium for Exelon patch
The launching symposium for Exelon Patch (rivastigmine transdermal patch) was held in Cheju, it was announced on December 18.
“Exelon is a cholinesterase inhibitor, and it is thought to exert its therapeutic effect...
Theraflu to go on sale in KoreaNovartis Korea says it will launch Theraflu, a brand of over-the-counter cold and flu medicines here.
Theraflu is produced in several forms and flavors, but is best known for...
|
Donwha receives presidential award for DW-1350Dongwha Pharm said on November 11 that following DW224a (zabofloxacin), it received, for the consecutive two years, the Presidential Award in 2008 Health Industry and Technology...
|
Viromed conducts phase I clinical trial for VM202 in China
The phase I clinical trial with VM202, a gene-based medicine for treatment of cardiovascular disease (CVD), has been conducted by ViroMed’s China partner Beijing Northland Biotech for peripheral artery disease (PAD, a...
Green Cross to conduct phase III trial for Peramivir
Green Cross Corporation plans to conduct its local phase III trials with peramivir injection, an important potential therapy for both seasonal influenza and pandemic preparedness as the Korea Food and Drug Administrat...
Ildong to co-develop GLP-1 fusion protein formulations with Genexine
Ildong Pharm and Genexine Co., a drug development biotech, entered into a collaboration agreement by signing a contract of the Product co-development.
The contract encompasses co-commercialization of GLP-1 (glucag...
AZK launches VRI discovery forum
AstraZeneca Korea and the Korea Health Industry Development Institute launched its third Venture Research Institute (VRI) Discovery Forum on December 3 to cooperate in developing new drugs and researching medical trea...
Boryung puts out ARB antihypertensive agent
Boryung says it has launched its new antihypertensive medicine containing losartan kalium, angiotensin II antagonist, through its own formulation technology.
This medicine works by preventing the action of a hormo...
